|By PR Newswire||
|February 12, 2014 08:26 PM EST||
LOS ALTOS, Calif., Feb. 12, 2014 /PRNewswire/ -- Altos Therapeutics, LLC, was recently informed by the United States Patent and Trademark Office that its pending patent application covering Altos' dopamine D2/D3 receptor antagonists for treating gastrointestinal diseases will be granted. The patent that issues will broadly and specifically cover the company's drug candidates, their pharmaceutical compositions, and their use for treating a number of important gastrointestinal conditions in humans, such as gastroparesis.
The issuance in the United States will mark a significant milestone in establishing patent coverage for this important family of compounds throughout the world. These compounds are currently being developed to meet unmet clinical needs in conditions that are responsive to dopamine D2/D3 receptor antagonist activity. Patent protection in the US and other countries around the world is expected to extend through 2031 under present laws.
"This represents an important milestone in the development of our company," stated Roger Whiting, Ph.D., President and CEO of Altos Therapeutics, "as extended intellectual property protection of our lead compounds will be a crucial aspect of our strategy to develop novel molecules for these disease states."
About Dopamine D2/D3 Receptor Antagonists
D2/D3 receptor antagonists have a multimodal therapeutic effect including stimulating gastric motility, normalizing gastric rhythm via actions on the enteric nervous system and diminishing nausea and vomiting in a variety of gastrointestinal conditions.
Gastroparesis is a chronic gastric motility disorder characterized by delayed gastric emptying. Symptoms include early satiety, postprandial fullness, nausea, vomiting, and abdominal discomfort. The current approved drug available in the United States for treating diabetic gastroparesis symptoms is metoclopramide, which suffers from a black box warning for tardive dyskinesia and is limited to acute use.
About Altos Therapeutics
Altos Therapeutics is committed to identifying and developing new medicines for gastrointestinal disorders in areas of high unmet medical need, including gastroparesis, functional dyspepsia, refractory gastroesophageal reflux disease (GERD), Parkinson's disease, and refractory nausea. Altos Therapeutics is a private pharmaceutical company located in Los Altos, California.
Roger Whiting, Co-founder, President and CEO
Email: [email protected]
SOURCE Altos Therapeutics, LLC
Sep. 27, 2016 01:00 PM EDT Reads: 2,800
Sep. 27, 2016 01:00 PM EDT Reads: 2,641
Sep. 27, 2016 01:00 PM EDT Reads: 1,585
Sep. 27, 2016 12:30 PM EDT Reads: 2,350
Sep. 27, 2016 12:30 PM EDT Reads: 1,686
Sep. 27, 2016 12:26 PM EDT Reads: 126
Sep. 27, 2016 12:15 PM EDT Reads: 198
Sep. 27, 2016 12:15 PM EDT Reads: 4,542
Sep. 27, 2016 12:15 PM EDT Reads: 3,185
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, will discuss how VPaaS enables you to move fast, creating scalable video experiences that reach your...
Sep. 27, 2016 12:00 PM EDT Reads: 1,053
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
Sep. 27, 2016 12:00 PM EDT Reads: 2,586
"We have several customers now running private clouds. They're not as large as they should be but it's getting there. The adoption challenge has been pretty simple. Look at the world today of virtualization vs cloud," stated Nara Rajagopalan, CEO of Accelerite, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Sep. 27, 2016 12:00 PM EDT Reads: 2,334
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Sep. 27, 2016 12:00 PM EDT Reads: 3,847
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Sep. 27, 2016 12:00 PM EDT Reads: 3,483
SYS-CON Events announced today that China Unicom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE F...
Sep. 27, 2016 12:00 PM EDT Reads: 1,780